MicroTech Medical (Hangzhou) Co., Ltd. Issues Positive Profit Alert for H1 2026
Hong Kong – July 30, 2026 – MicroTech Medical (Hangzhou) Co., Ltd. (Stock Code: 2235), a key player in the medical device industry, has released a positive profit alert indicating a significant turnaround in its financial performance for the first half of 2026.
Key Highlights for Investors
- Substantial Revenue Growth: The company estimates revenue of not less than RMB400 million for the six months ended June 30, 2026, marking a robust year-on-year increase of at least 63% compared to RMB246 million in the same period last year.
- Return to Profitability: Net profit attributable to shareholders is projected to reach not less than RMB36 million, a remarkable turnaround from a net loss of RMB2 million in the first half of 2025.
- Growth Drivers:
- Continuous strong growth in sales of the group’s flagship product, the Continuous Glucose Monitoring System (CGMS).
- Sustained robust development in other key products, including the patch insulin pump system and blood glucose monitoring system.
- Improved gross profit margin, primarily due to higher revenue contribution from CGMS and enhanced production scale efficiency.
- Significantly optimized operational efficiency, with a marked reduction in the ratio of selling and administrative expenses to income as a result of streamlined marketing activities.
- Pending Official Results: The financial figures are based on unaudited consolidated management accounts and may be subject to adjustments, as the final results will be published by the end of August 2026.
Price-Sensitive Information for Shareholders
The dramatic shift from a net loss to a net profit, along with the strong revenue growth and improved margins, are highly price-sensitive developments that could have a material impact on the company’s share price. These improvements signal a strengthening business model and enhanced operational execution, which are likely to boost investor confidence.
However, shareholders should note that the results are preliminary and unaudited. The actual financial results may differ once the accounts are finalized and reviewed by the auditor and audit committee.
Management Commentary
The management attributes the positive trends primarily to the robust performance of the CGMS product, expanding scale efficiencies, and disciplined cost controls. The company has committed to further optimizing its operations and marketing strategies to sustain this trajectory.
Board Composition
As of the date of the announcement, the Board consists of executive directors Dr. Zheng Pan (Chairman), Dr. Yu Fei, Dr. Shi Yonghui, and Ms. Liu Xiu; non-executive directors Mr. Mao Shuo and Ms. Gao Yun; and independent non-executive directors Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin, and Dr. Cheng Hua.
Investor Advisory
Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company until the final audited results are released.
Disclaimer: This article is based on the company’s unaudited management accounts and forward-looking statements. Actual results may differ from those indicated. Investors are encouraged to refer to the official announcement and await the release of the audited financial statements for complete and validated information before making investment decisions.
